Why Did Esperion Therapeutics Inc (ESPR) Soar 15.23% on Positive Q2 Earnings?

Esperion Therapeutics Inc (ESPR) surged 15.23% in pre-market trading on September 4, 2025, marking a significant rise in its stock price.

Esperion Therapeutics recently reported its Q2 2025 earnings, with an EPS of -$0.02, which exceeded the consensus estimate of -$0.17 by $0.15. This positive earnings report has likely contributed to the recent surge in the company's stock price.

Additionally, there has been speculation and analysis regarding the future price targets for Esperion Therapeutics. While specific price targets were not detailed, the market's positive reaction suggests that investors are optimistic about the company's prospects.

Overall, the recent earnings report and market sentiment have driven Esperion Therapeutics' stock price higher, reflecting investor confidence in the company's performance and future potential.